Skip to main content

Table 5 Association of Her2 neu expression with clinicopathologic parameters in prostatic acinar adenocarcinoma

From: Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma

   n(%) P-Value
Positive (n = 28) Negative (n = 95)
Age Group ≤70 years 16(57.1) 61(64.2) 0.497
> 70 years 12(42.9) 34(35.8)
Total gleason score 6 4(14.3) 35(36.8) 0.029
7 5(17.9) 24(25.3)
8 8(28.6) 19(20)
9 11(39.3) 17(17.9)
WHO grade groupª Grade 1 4(14.3) 35(36.8) 0.014
Grade 2 3(10.7) 22(23.2)
Grade 3 2(7.1) 2(2.1)
Grade 4 8(28.6) 19(20)
Grade 5 11(39.3) 17(17.9)
Tumor Quantification < 10% 3(10.7) 20(21.1) 0.028
10–50% 4(14.3) 31(32.6)
> 50% 21(75) 44(46.3)
Perineural invasion Present 14(50) 32(33.7) 0.117
Absent 14(50) 63(66.3)
Lymphovascular invasionª Present 0(0) 3(3.2) 1.000
Absent 28(100) 92(96.8)
Extraprostatic extensionª Present 0(0) 7(7.4) 0.349
Absent 28(100) 88(92.6)
Seminal vesicle invasion ª Present 2(7.1) 2(2.1) 0.222
Absent 26(92.9) 93(97.9)
Recurrence Yes 19(67.9) 14(14.7) < 0.001
No 9(32.1) 81(85.3)
EGFR Positive 8(28.6) 92(96.8) < 0.001
Negative 20(71.4) 3(3.2)
  1. Chi square test was applied
  2. ªFisher exact test applied
  3. P-Value≤0.05, considered as significant